Angiotensin II type-1 receptor antagonist attenuates LPS-induced acute lung injury

Cytokine

Volumn 48, Issue 3, 2009, Pages 246-253

  Wang, Fei ^a   Xia, Zhao Fan ^b   Chen, Xu Lin ^a   Jia, Yi Tao ^b   Wang, Yong Jie ^a   Ma, Bing ^b  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Acute lung injury; Angiotensin II type 1 receptor; Interleukin 1 ; Lipopolysaccharide; Tumor necrosis factor

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; MESSENGER RNA; NUCLEAR FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ZD 7155;

ACUTE LUNG INJURY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; GENE EXPRESSION; HISTOPATHOLOGY; INFLAMMATION; LUNG PARENCHYMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZATION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION;

ACUTE LUNG INJURY; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BLOTTING, WESTERN; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-1BETA; LIPOPOLYSACCHARIDES; LUNG; MALE; MICE; NAPHTHYRIDINES; NF-KAPPA B; RECEPTOR, ANGIOTENSIN, TYPE 1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSCRIPTION FACTOR AP-1; TUMOR NECROSIS FACTOR-ALPHA;

MUS;

EID: 70350031614     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2009.08.001     Document Type: Article

References (50)

1. Goodman R.B., Strieter R.M., Martin D.P., Steinberg K.P., Milberg J.A., Maunder R.J., et al. Inflammatory cytokines in patients with persistence of the acute respiratory distress syndrome. Am J Respir Crit Care Med 154 (1996) 602-611
2. Ware L.B., and Matthay M.A. The acute respiratory distress syndrome. N Engl J Med 234 (2000) 1334-1349
3. Vincent J.L., Sakr Y., and Ranieri V.M. Epidemiology and outcome of acute respiratory failure in intensive care unit patients. Crit Care Med 31 (2003) S296-S299
4. Brigham K.L., and Meyrick B. Endotoxin and lung injury. Am Rev Respir Dis 133 (1986) 913-927
5. Worthen G.S., Haslett C., Rees A.J., Gumbay R.S., Henson J.E., and Henson P.M. Neutrophil-mediated pulmonary vascular injury. Synergistic effect of trace amounts of lipopolysaccharide and neutrophil stimuli on vascular permeability and neutrophil sequestration in the lung. Am Rev Respir Dis 136 (1987) 19-28
6. Goodman R.B., Pugin J., Lee J.S., and Matthay M.A. Cytokine-mediated inflammation in acute lung injury. Cytokine Growth Factor Rev 14 (2003) 523-535
7. Meduri G.U., Headley S., Kohler G., Stentz F., Tolley E., Umberger R., et al. Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS: plasma IL-1 beta and IL-6 levels are consistent and efficient predictors of outcome over time. Chest 107 (1995) 1062-1073
8. Kambayashi Y., Bardhan S., Takahashi K., Tsuzuki S., Inui H., Hamakubo T., et al. Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition. J Biol Chem 268 (1993) 24543-24546
9. Mukoyama M., Nakajima M., Horiuchi M., Sasamura H., Pratt R.E., and Dzau V.J. Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. J Biol Chem 268 (1993) 24539-24542
10. Zhuo J., Moeller I., Jenkins T., Chai S.Y., Allen A.M., Ohishi M., et al. Mapping tissue angiotensin-converting enzyme and angiotensin AT1, AT2 and AT4 receptors. Hypertension 16 (1998) 2027-2037
11. Sadoshima J. Versatility of the angiotensin II type I receptor. Circ Res 82 (1998) 1352-1355
12. Touyz R.M., and Schiffrin E.L. Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev 52 (2000) 639-672
13. Phillips M.I., and Kagiyama S. Angiotensin II as a pro-inflammatory mediator. Curr Opin Investig Drugs 3 (2002) 569-577
14. Cheng Z.J., Vapaatalo H., and Mervaala E. Angiotensin II and vascular inflammation. Med Sci Monit 11 (2005) RA194-RA205
15. Tamarat R., Silvestre J.S., Durie M., and Levy B.I. Angiotensin II angiogenic effect in vivo involves vascular endothelial growth factor- and inflammation-related pathways. Lab Invest 82 (2002) 747-756
16. Pastore L., Tessitore A., Martinotti S., Toniato E., Alesse E., Bravi M.C., et al. Angiotensin II stimulates intercellular adhesion molecule-1 (ICAM-1) expression by human vascular endothelial cells and increases soluble ICAM-1 release in vivo. Circulation 100 (1999) 1646-1652
17. Zhang H., and Sun G.Y. LPS induces permeability injury in lung microvascular endothelium via AT1 receptor. Arch Biochem Biophys 441 (2005) 75-83
18. Ruiz-Ortega M., Rupérez M., Esteban V., Rodríguez-Vita J., Sánchez-López E., Carvajal G., et al. Angiotensin II: a key factor in the inflammatory and fibrotic response in kidney diseases. Nephrol Dial Transplant 21 (2006) 16-20
19. Peng X., Hassoun P.M., Sammani S., McVerry B.J., Burne M.J., Rabb H., et al. Protective effects of sphingosine 1-phosphate in murine endotoxin-induced inflammatory lung injury. Am J Resp Crit Care Med 169 (2004) 1245-1251
20. Gloor B., Blinman T.A., Rigberg D.A., Todd K.E., Lane J.S., Hines O.J., et al. Kupffer cell blockade reduces hepatic and systemic cytokine levels and lung injury in hemorrhagic pancreatitis in rats. Pancreas 21 (2000) 414-420
21. Dunn C.W., and Horton J.W. Role of angiotensin II in neonatal sepsis. Circ Shock 40 (1993) 144-150
22. Bader M., Peters J., Baltatu O., Müller D.N., Luft F.C., and Ganten D. Tissue renin-angiotensin systems: new insights from experimental animal models in hypertension research. J Mol Med 79 (2001) 76-102
23. Shimizu A., Yamagata T., Tatsuno H., Esato M., Ueyama T., Hayano T., et al. Radio-frequency catheter ablation therapy in elderly patients with supraventricular tachycardia. Nippon Ronen Igakkai Zasshi 35 (1998) 451-457
24. Tadros T., Traber D.L., Heggers J.P., and Herndon D.N. Angiotensin II inhibitor DuP753 attenuates burn- and endotoxin-induced gut ischemia, lipid peroxidation, mucosal permeability, and bacterial translocation. Ann Surg 231 (2000) 566-576
25. Tadros T., Traber D.L., and Herndon D.N. Trauma- and sepsis-induced hepatic ischemia and reperfusion injury: role of angiotensin II. Arch Surg 135 (2000) 766-772
26. Ruiz-Ortega M., Lorenzo O., Suzuki Y., Rupérez M., and Egido J. Proinflammatory actions of angiotensin II. Curr Opin Nephrol Hypertens 10 (2001) 321-329
27. Otsuka M., Takahashi H., Shiratori M., Chiba H., and Abe S. Reduction of bleomycin induced lung 15 fibrosis by candesartan cilexetil, an angiotensin II type 1 receptor antagonist. Thorax 59 (2004) 31-38
28. Jalowy A., Schulz R., and Heusch G. AT1 receptor blockade in experimental myocardial ischemia/reperfusion. J Am Soc Nephrol 10 (1999) S129-S136
29. Yang B.C., Phillips M.I., Zhang Y.C., Kimura B., Shen L.P., Mehta P., et al. Critical role of AT1 receptor expression after ischemia/reperfusion in isolated rat hearts: beneficial effect of antisense oligodeoxynucleotides directed at AT1 receptor mRNA. Circ Res 83 (1998) 552-559
30. Petnehazy T., Stokes K.Y., Russell J.M., and Granger D.N. Angiotensin II type-1 receptor antagonism attenuates the inflammatory and thrombogenic responses to hypercholesterolemia in venules. Hypertension 45 (2005) 209-215
31. Papademetriou V. The potential role of AT1-receptor blockade in the prevention and reversal of atherosclerosis. J Hum Hypertens 16 (2002) S34-S41
32. Bove C.M., Gilson W.D., Scott C.D., Epstein F.H., Yang Z., Dimaria J.M., et al. The angiotensin II type-2 receptor and improved adjacent region function post-MI. J Cardiovasc Magn Reson 7 (2005) 459-464
33. Yang Z., Bove C.M., French B.A., Epstein F.H., Berr S.S., DiMaria J.M., et al. Angiotensin II type 2 receptor overexpression preserves left ventricular function after myocardial infarction. Circulation 106 (2002) 106-111
34. Hales C.A., Elsasser T.H., Ocampo P., and Efimova O. TNF-alpha in smoke inhalation lung injury. J Appl Physiol 82 (1997) 1433-1437
35. Chen X.L., Xia Z.F., Ben D.F., Wang G.Q., and Wei D. Role of p38 mitogen-activated protein kinase in lung injury after burn trauma. Shock 19 (2003) 475-479
36. Yoshinari D., Takeyoshi I., Koibuchi Y., Matsumoto K., Kawashima Y., Koyama T., et al. Effects of a dual inhibitor of tumor necrosis factoralpha and interleukin-1 on lipopolysaccharide-induced lung injury in rats: involvement of the p38 mitogen-activated protein kinase pathway. Crit Care Med 29 (2001) 628-634
37. Otani Y., Takeyoshi I., Koibuchi Y., Matsumoto K., Muramoto M., and Morishita Y. The effect of FR167653 on pulmonary ischemia-reperfusion injury in rats. J Heart Lung Transplant 19 (2000) 377-383
38. Mezzano S., Aros C., Droguett A., Burgos M.E., Ardiles L., Flores C., et al. NF-kappaB activation and overexpression of regulated genes in human diabetic nephropathy. Nephrol Dial Transplant 19 (2004) 2505-2512
39. Dörffel Y., Lätsch C., Stuhlmüller B., Schreiber S., Scholze S., Burmester G.R., et al. Preactivated peripheral blood monocytes in patients with essential hypertension. Hypertension 34 (1999) 113-117
40. Yamamoto K., Shioi T., Uchiyama K., Miyamoto T., Sasayama S., and Matsumori A. Attenuation of virus-induced myocardial injury by inhibition of the angiotensin II type 1 receptor signal and decreased nuclear factor-kappa B activation in knockout mice. J Am Coll Cardiol 42 (2003) 2000-2006
41. Bergmann M., Hart L., Lindsay M., Barnes P.J., and Newton R. IkappaBalpha degradation and nuclear factor-kappaB DNA binding are insufficient for interleukin-1beta and tumor necrosis factor-alpha-induced kappaB-dependent transcription. Requirement for an additional activation pathway. J Biol Chem 273 (1998) 6607-6610
42. Barnes P.J., and Karin M. Nuclear factor-κB, a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336 (1997) 1066-1071
43. Egido J., Hernández-Presa M.A., Tuñón J., Blancocolio L.M., Ortego M., Suzuki Y., et al. Transcription factor-κB and cardiovascular disease. Cardiovasc Risk Factor 9 (2000) 159-168
44. Ashizawa M., Miyazaki M., Koji T., Isomoto H., Ozono Y., Harada T., et al. Expression of nuclear factor kappa B (NF-κB) assessed by Southwestern histochemistry (SWH) is associated with renal injury in IgA nephropathy (IgAN) [abstract]. J Am Soc Nephrol 10 (1999) A95
45. Ruiz-Ortega M., Bustos C., Hernández-Presa M.A., Lorenzo O., Plaza J.J., and Egido J. Angiotensin II participates in mononuclear cell recruitment in the kidney through nuclear factor-kappa B activation and monocyte chemoattractant protein-1 gene expression. J Immunol 161 (1998) 430-439
46. Han Y., Runge M.S., and Brasier A.R. Angiotensin II induces interleukin-6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factor-kappa B transcription factors. Circ Res 84 (1999) 695-703
47. Pueyo M.E., Gonzalez W., Nicoletti A., Savoie F., Arnal J.F., and Michel J.B. Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-κB activation induced by intracellular oxidative stress. Arterioscler Thromb Vasc Biol 20 (2000) 645-651
48. Abraham E. Nuclear factor-κB and its role in sepsis-associated organ failure. J Infect Dis 187 (2003) S362-S369
49. Eder J. Tumor necrosis factor alpha and interleukin 1 signalling: do MAPKK kinases connect it all? Trends. Pharmacol Sci 18 (1997) 319-322
50. Bullock G.R., Steyaert I., Bilbe G., Carey R.M., Kips J., De Paepe B., et al. Distribution of type-1 and type-2 angiotensin receptors in the normal human lung and in lungs from patients with chronic obstructive pulmonary disease. Histochem Cell Biol 115 (2001) 117-124